Program
sapablursen
Also written as “Sapablursen” and “IONIS TMPRSS6-Lrx”.
Its studies are mostly in Polycythemia Vera · beta-Thalassemia · Thalassemia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ionis Pharmaceuticals | 30 open or running | phase 2since Aug 14, 2019 | May 18, 2017 | none ahead |
| Ono Pharmaceutical | 11 open or running | phase 3since Feb 18, 2026 | Feb 18, 2026 | Sep 2028phase 3 · NCT07429266 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 18, 2017First study: phase 1 study in ThalassemiaNew to Ionis PharmaceuticalsIonis Pharmaceuticals · NCT03165864 · 36 enrolled · Australia
- Aug 14, 2019Phase 2 study in beta-ThalassemiaIonis Pharmaceuticals · NCT04059406 · 29 enrolled · Australia, Greece, Lebanon and more
- Nov 20, 2021Phase 2 study in Polycythemia VeraIonis Pharmaceuticals · NCT05143957 · 50 enrolled · United States, Australia, Canada and more
- Feb 18, 2026Ono Pharmaceutical's first study: phase 3 study in Polycythemia VeraNew to Ono PharmaceuticalOno Pharmaceutical · NCT07429266 · 250 planned · United States, Australia, Austria and more
Ahead
- Sep 2028Primary completion: phase 3 study in Polycythemia VeraOno Pharmaceutical · NCT07429266
TargetBeta
“An antisense oligonucleotide (ASO) targeting the transmembrane protease serine 6 (TMPRSS6) mRNA and ”NCIt, by rule
Other programs on TMPRSS6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| AG-236rule | Agios Pharmaceuticals | phase 3 | 2 |
| Anti-TMPRSS6 Monoclonal Antibody DISC-3405rule | disc-medicine-inc | phase 2 | 6 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07429266Polycythemia Vera · United States, Australia, Austria and more | 3 | Recruiting | Ono Pharmaceutical | Sep 2028 | 250 |
| NCT05143957Polycythemia Vera · United States, Australia, Canada and more | 2 | Completed | Ionis Pharmaceuticals | Jun 26, 2025 | 50 |
| NCT04059406beta-Thalassemia · Australia, Greece, Lebanon and more | 2 | Terminated | Ionis Pharmaceuticals | Mar 28, 2023 | 29 |
| NCT03165864Thalassemia · Australia | 1 | Completed | Ionis Pharmaceuticals | Sep 25, 2018 | 36 |
How it is read
Names in the registry
- “sapablursen”, 2 entries
- “Sapablursen”, 1 entry
- “IONIS TMPRSS6-Lrx”, 1 entry
Conditions, from the studies’ own filings
- Polycythemia Vera, 2 studies
- beta-Thalassemia, 1 study
- Thalassemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.